Johnson & Johnson Innovative Medicine careers
1 verified opening
Johnson & Johnson Innovative Medicine is the prescription drug half of a company incorporated in New Jersey in 1887. The other half is MedTech, and there is no third segment. Its work covers six therapeutic areas: oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. Segment sales reached $60.4 billion in 2025, $36.3 billion of that in the United States.
The pressure shaping the business is patent expiry. STELARA, for years one of its largest products, lost ground to biosimilar competitors during 2025, and the company put that decline's drag at 10.4 percent of the segment's worldwide operational sales. Its own annual report names loss of exclusivity as the standing risk here: when a patent goes, generics and biosimilars arrive and sales fall away. What follows on behind is weighted toward blood cancers, including CARVYKTI, a CAR-T cell therapy for relapsed or refractory multiple myeloma, the bispecific antibodies TECVAYLI and TALVEY, and RYBREVANT paired with LAZCLUZE for EGFR-mutated non-small cell lung cancer. Of the 63 manufacturing plants Johnson & Johnson subsidiaries run, three in the United States and 16 elsewhere belong to this segment; the whole company employed roughly 138,200 people as of year-end 2025.